If a change in NHE1 activity also affects LPS-induced impact on cytokines, then the development of specific and potent NHE inhibitors/agonists may produce a cure for LPS induced-malfunction, such as organ failures in sepsis and septic shock, in a clinic. The gene discussed is SLC9A1; the disease is Shock.